Lift Enhancement for Low-Aspect-Ratio Wings with Periodic Excitation

In an effort to enhance lift on low-aspect-ratio rectangular flat-plate wings in low-Reynolds-number post-stall flows, periodic injection of momentum is considered along the trailing edge in this numerical study. The purpose of actuation is not to reattach the flow but to change the dynamics of the wake vortices such that the resulting lift force is increased. Periodic forcing is observed to be effective in increasing lift for various aspect ratios and angles of attack, achieving a similar lift enhancement attained by steady forcing with less momentum input. Through the investigation on the influence of the actuation frequency, it is also found that there exists a frequency at which the flow locks on to a time-periodic high-lift state

Closed-Loop Control of Leading Edge Vorticity on a 3D Wing: Simulations and Low-Dimensional Models

We study model-based feedback control of the low-Reynolds-number flow over a flat plate at large angles of attack, in both two and three dimensions. Our long-term goal is to be able to manipulate the leading-edge vortices that form on low-aspect-ratio wings at high angles of attack, and that often contribute to exceptionally large lift coefficients. Intwo-dimensional simulations, we present a model-based feedback controller that uses an observer to reconstruct the entire flow field from velocity measurements at three locations, and stabilizes the flow at an angle of attack for which the natural flow state is periodic shedding. In three-dimensional simulations, we use open-loop forcing to study actuator placement, and conclude that trailing-edge actuation is more effective than leading-edge actuation in influencing the forces on the plate, as well as the wake structures. Finally, we present initial results towards extending our model-based control design to the 3D setting, and apply a selective frequency damping method to find unstable equilibrium flow fields in 3D simulations

Diffuse Galactic Soft Gamma-Ray Emission

The Galactic diffuse soft gamma-ray (30-800 keV) emission has been measured from the Galactic Center by the HIREGS balloon-borne germanium spectrometer to determine the spectral characteristics and origin of the emission. The resulting Galactic diffuse continuum is found to agree well with a single power-law (plus positronium) over the entire energy range, consistent with RXTE and COMPTEL/CGRO observations at lower and higher energies, respectively. We find no evidence of spectral steepening below 200 keV, as has been reported in previous observations. The spatial distribution along the Galactic ridge is found to be nearly flat, with upper limits set on the longitudinal gradient, and with no evidence of an edge in the observed region. The soft gamma-ray diffuse spectrum is well modeled by inverse Compton scattering of interstellar radiation off of cosmic-ray electrons, minimizing the need to invoke inefficient nonthermal bremsstrahlung emission. The resulting power requirement is well within that provided by Galactic supernovae. We speculate that the measured spectrum provides the first direct constraints on the cosmic-ray electron spectrum below 300 MeV.Comment: 26 pages, 7 figure, submitted to Ap

Changes in the in vitro pharmacodynamic properties of metoprolol in atria isolated from spontaneously hypertensive rats.

SUMMARY 1. The present study addressed possible changes in the dissociation constant of metoprolol and its inverse agonist activity in spontaneously hypertensive rats (SHR). In addition, a possible correlation between cardiac hypertrophy and the inverse agonist activity of metoprolol was explored. 2. In order to determine the dissociation constant (expressed as the pKb) of metoprolol, a cumulative concentration–response curve to noradrenaline was constructed in the absence or presence of metoprolol (0.1, 1 or 10 mmol/L). In a second experiment, a cumulative concentration–response curve to metoprolol was constructed to determine its inverse agonist activity. 3. The ventricular weight of SHR was significantly greater compared with Wistar-Kyoto (WKY) rats. A rightward shift of the concentration–response curve to noradrenaline was observed in SHR compared with WKY rats. The pKb of metoprolol was smaller in SHR compared with WKY rats (6.35 ± 0.14 vs 6.99 ± 0.12, respectively; P < 0.05). No difference was observed in the maximal response (Emax) of the concentration–time effect of metoprolol in WKY rats and SHR (−29.1 ± 7.1 vs −28.2 ± 8.5%, respectively; n = 6 for both). However, the concentration of metoprolol eliciting a half-maximal effect (expressed as the pEC50) was significantly smaller in SHR compared with WKY rats (4.82 ± 0.07 vs 5.29 ± 0.13, respectively; n = 6; P < 0.05). Although a significant correlation (r = – 0.876) between the ventricular weight/bodyweight (VW/ BW) ratio and the pEC50 of the chronotropic effect of metoprolol was found, no relationship (r = – 0.257) was found between the VW/BW ratio and Emax. 4. In summary, the present study provides the first evidence of a change in the in vitro pharmacodynamic properties of metoprolol in SHR. The sympathetic overactivity present in SHR not only reduces the positive chronotropic effect of noradrenaline, but also diminishes the constant dissociation of metoprolol from atrial b1-adrenoceptors and its inverse agonist activity. A significant correlation between the VW/BW ratio and the inverse agonist potency of metoprolol was found, suggesting a possible link between cardiac hypertrophy and the reduction of the inverse agonist activity of metoprolol.n = 6; P < 0.05). Although a significant correlation (r = – 0.876) between the ventricular weight/bodyweight (VW/ BW) ratio and the pEC50 of the chronotropic effect of metoprolol was found, no relationship (r = – 0.257) was found between the VW/BW ratio and Emax. 4. In summary, the present study provides the first evidence of a change in the in vitro pharmacodynamic properties of metoprolol in SHR. The sympathetic overactivity present in SHR not only reduces the positive chronotropic effect of noradrenaline, but also diminishes the constant dissociation of metoprolol from atrial b1-adrenoceptors and its inverse agonist activity. A significant correlation between the VW/BW ratio and the inverse agonist potency of metoprolol was found, suggesting a possible link between cardiac hypertrophy and the reduction of the inverse agonist activity of metoprolol.r = – 0.876) between the ventricular weight/bodyweight (VW/ BW) ratio and the pEC50 of the chronotropic effect of metoprolol was found, no relationship (r = – 0.257) was found between the VW/BW ratio and Emax. 4. In summary, the present study provides the first evidence of a change in the in vitro pharmacodynamic properties of metoprolol in SHR. The sympathetic overactivity present in SHR not only reduces the positive chronotropic effect of noradrenaline, but also diminishes the constant dissociation of metoprolol from atrial b1-adrenoceptors and its inverse agonist activity. A significant correlation between the VW/BW ratio and the inverse agonist potency of metoprolol was found, suggesting a possible link between cardiac hypertrophy and the reduction of the inverse agonist activity of metoprolol.50 of the chronotropic effect of metoprolol was found, no relationship (r = – 0.257) was found between the VW/BW ratio and Emax. 4. In summary, the present study provides the first evidence of a change in the in vitro pharmacodynamic properties of metoprolol in SHR. The sympathetic overactivity present in SHR not only reduces the positive chronotropic effect of noradrenaline, but also diminishes the constant dissociation of metoprolol from atrial b1-adrenoceptors and its inverse agonist activity. A significant correlation between the VW/BW ratio and the inverse agonist potency of metoprolol was found, suggesting a possible link between cardiac hypertrophy and the reduction of the inverse agonist activity of metoprolol.r = – 0.257) was found between the VW/BW ratio and Emax. 4. In summary, the present study provides the first evidence of a change in the in vitro pharmacodynamic properties of metoprolol in SHR. The sympathetic overactivity present in SHR not only reduces the positive chronotropic effect of noradrenaline, but also diminishes the constant dissociation of metoprolol from atrial b1-adrenoceptors and its inverse agonist activity. A significant correlation between the VW/BW ratio and the inverse agonist potency of metoprolol was found, suggesting a possible link between cardiac hypertrophy and the reduction of the inverse agonist activity of metoprolol.max. 4. In summary, the present study provides the first evidence of a change in the in vitro pharmacodynamic properties of metoprolol in SHR. The sympathetic overactivity present in SHR not only reduces the positive chronotropic effect of noradrenaline, but also diminishes the constant dissociation of metoprolol from atrial b1-adrenoceptors and its inverse agonist activity. A significant correlation between the VW/BW ratio and the inverse agonist potency of metoprolol was found, suggesting a possible link between cardiac hypertrophy and the reduction of the inverse agonist activity of metoprolol.in vitro pharmacodynamic properties of metoprolol in SHR. The sympathetic overactivity present in SHR not only reduces the positive chronotropic effect of noradrenaline, but also diminishes the constant dissociation of metoprolol from atrial b1-adrenoceptors and its inverse agonist activity. A significant correlation between the VW/BW ratio and the inverse agonist potency of metoprolol was found, suggesting a possible link between cardiac hypertrophy and the reduction of the inverse agonist activity of metoprolol.b1-adrenoceptors and its inverse agonist activity. A significant correlation between the VW/BW ratio and the inverse agonist potency of metoprolol was found, suggesting a possible link between cardiac hypertrophy and the reduction of the inverse agonist activity of metoprolol.= 6 for both). However, the concentration of metoprolol eliciting a half-maximal effect (expressed as the pEC50) was significantly smaller in SHR compared with WKY rats (4.82 ± 0.07 vs 5.29 ± 0.13, respectively; n = 6; P < 0.05). Although a significant correlation (r = – 0.876) between the ventricular weight/bodyweight (VW/ BW) ratio and the pEC50 of the chronotropic effect of metoprolol was found, no relationship (r = – 0.257) was found between the VW/BW ratio and Emax. 4. In summary, the present study provides the first evidence of a change in the in vitro pharmacodynamic properties of metoprolol in SHR. The sympathetic overactivity present in SHR not only reduces the positive chronotropic effect of noradrenaline, but also diminishes the constant dissociation of metoprolol from atrial b1-adrenoceptors and its inverse agonist activity. A significant correlation between the VW/BW ratio and the inverse agonist potency of metoprolol was found, suggesting a possible link between cardiac hypertrophy and the reduction of the inverse agonist activity of metoprolol.n = 6; P < 0.05). Although a significant correlation (r = – 0.876) between the ventricular weight/bodyweight (VW/ BW) ratio and the pEC50 of the chronotropic effect of metoprolol was found, no relationship (r = – 0.257) was found between the VW/BW ratio and Emax. 4. In summary, the present study provides the first evidence of a change in the in vitro pharmacodynamic properties of metoprolol in SHR. The sympathetic overactivity present in SHR not only reduces the positive chronotropic effect of noradrenaline, but also diminishes the constant dissociation of metoprolol from atrial b1-adrenoceptors and its inverse agonist activity. A significant correlation between the VW/BW ratio and the inverse agonist potency of metoprolol was found, suggesting a possible link between cardiac hypertrophy and the reduction of the inverse agonist activity of metoprolol.r = – 0.876) between the ventricular weight/bodyweight (VW/ BW) ratio and the pEC50 of the chronotropic effect of metoprolol was found, no relationship (r = – 0.257) was found between the VW/BW ratio and Emax. 4. In summary, the present study provides the first evidence of a change in the in vitro pharmacodynamic properties of metoprolol in SHR. The sympathetic overactivity present in SHR not only reduces the positive chronotropic effect of noradrenaline, but also diminishes the constant dissociation of metoprolol from atrial b1-adrenoceptors and its inverse agonist activity. A significant correlation between the VW/BW ratio and the inverse agonist potency of metoprolol was found, suggesting a possible link between cardiac hypertrophy and the reduction of the inverse agonist activity of metoprolol.50 of the chronotropic effect of metoprolol was found, no relationship (r = – 0.257) was found between the VW/BW ratio and Emax. 4. In summary, the present study provides the first evidence of a change in the in vitro pharmacodynamic properties of metoprolol in SHR. The sympathetic overactivity present in SHR not only reduces the positive chronotropic effect of noradrenaline, but also diminishes the constant dissociation of metoprolol from atrial b1-adrenoceptors and its inverse agonist activity. A significant correlation between the VW/BW ratio and the inverse agonist potency of metoprolol was found, suggesting a possible link between cardiac hypertrophy and the reduction of the inverse agonist activity of metoprolol.r = – 0.257) was found between the VW/BW ratio and Emax. 4. In summary, the present study provides the first evidence of a change in the in vitro pharmacodynamic properties of metoprolol in SHR. The sympathetic overactivity present in SHR not only reduces the positive chronotropic effect of noradrenaline, but also diminishes the constant dissociation of metoprolol from atrial b1-adrenoceptors and its inverse agonist activity. A significant correlation between the VW/BW ratio and the inverse agonist potency of metoprolol was found, suggesting a possible link between cardiac hypertrophy and the reduction of the inverse agonist activity of metoprolol.max. 4. In summary, the present study provides the first evidence of a change in the in vitro pharmacodynamic properties of metoprolol in SHR. The sympathetic overactivity present in SHR not only reduces the positive chronotropic effect of noradrenaline, but also diminishes the constant dissociation of metoprolol from atrial b1-adrenoceptors and its inverse agonist activity. A significant correlation between the VW/BW ratio and the inverse agonist potency of metoprolol was found, suggesting a possible link between cardiac hypertrophy and the reduction of the inverse agonist activity of metoprolol.in vitro pharmacodynamic properties of metoprolol in SHR. The sympathetic overactivity present in SHR not only reduces the positive chronotropic effect of noradrenaline, but also diminishes the constant dissociation of metoprolol from atrial b1-adrenoceptors and its inverse agonist activity. A significant correlation between the VW/BW ratio and the inverse agonist potency of metoprolol was found, suggesting a possible link between cardiac hypertrophy and the reduction of the inverse agonist activity of metoprolol.b1-adrenoceptors and its inverse agonist activity. A significant correlation between the VW/BW ratio and the inverse agonist potency of metoprolol was found, suggesting a possible link between cardiac hypertrophy and the reduction of the inverse agonist activity of metoprolol.50) was significantly smaller in SHR compared with WKY rats (4.82 ± 0.07 vs 5.29 ± 0.13, respectively; n = 6; P < 0.05). Although a significant correlation (r = – 0.876) between the ventricular weight/bodyweight (VW/ BW) ratio and the pEC50 of the chronotropic effect of metoprolol was found, no relationship (r = – 0.257) was found between the VW/BW ratio and Emax. 4. In summary, the present study provides the first evidence of a change in the in vitro pharmacodynamic properties of metoprolol in SHR. The sympathetic overactivity present in SHR not only reduces the positive chronotropic effect of noradrenaline, but also diminishes the constant dissociation of metoprolol from atrial b1-adrenoceptors and its inverse agonist activity. A significant correlation between the VW/BW ratio and the inverse agonist potency of metoprolol was found, suggesting a possible link between cardiac hypertrophy and the reduction of the inverse agonist activity of metoprolol.n = 6; P < 0.05). Although a significant correlation (r = – 0.876) between the ventricular weight/bodyweight (VW/ BW) ratio and the pEC50 of the chronotropic effect of metoprolol was found, no relationship (r = – 0.257) was found between the VW/BW ratio and Emax. 4. In summary, the present study provides the first evidence of a change in the in vitro pharmacodynamic properties of metoprolol in SHR. The sympathetic overactivity present in SHR not only reduces the positive chronotropic effect of noradrenaline, but also diminishes the constant dissociation of metoprolol from atrial b1-adrenoceptors and its inverse agonist activity. A significant correlation between the VW/BW ratio and the inverse agonist potency of metoprolol was found, suggesting a possible link between cardiac hypertrophy and the reduction of the inverse agonist activity of metoprolol.r = – 0.876) between the ventricular weight/bodyweight (VW/ BW) ratio and the pEC50 of the chronotropic effect of metoprolol was found, no relationship (r = – 0.257) was found between the VW/BW ratio and Emax. 4. In summary, the present study provides the first evidence of a change in the in vitro pharmacodynamic properties of metoprolol in SHR. The sympathetic overactivity present in SHR not only reduces the positive chronotropic effect of noradrenaline, but also diminishes the constant dissociation of metoprolol from atrial b1-adrenoceptors and its inverse agonist activity. A significant correlation between the VW/BW ratio and the inverse agonist potency of metoprolol was found, suggesting a possible link between cardiac hypertrophy and the reduction of the inverse agonist activity of metoprolol.50 of the chronotropic effect of metoprolol was found, no relationship (r = – 0.257) was found between the VW/BW ratio and Emax. 4. In summary, the present study provides the first evidence of a change in the in vitro pharmacodynamic properties of metoprolol in SHR. The sympathetic overactivity present in SHR not only reduces the positive chronotropic effect of noradrenaline, but also diminishes the constant dissociation of metoprolol from atrial b1-adrenoceptors and its inverse agonist activity. A significant correlation between the VW/BW ratio and the inverse agonist potency of metoprolol was found, suggesting a possible link between cardiac hypertrophy and the reduction of the inverse agonist activity of metoprolol.r = – 0.257) was found between the VW/BW ratio and Emax. 4. In summary, the present study provides the first evidence of a change in the in vitro pharmacodynamic properties of metoprolol in SHR. The sympathetic overactivity present in SHR not only reduces the positive chronotropic effect of noradrenaline, but also diminishes the constant dissociation of metoprolol from atrial b1-adrenoceptors and its inverse agonist activity. A significant correlation between the VW/BW ratio and the inverse agonist potency of metoprolol was found, suggesting a possible link between cardiac hypertrophy and the reduction of the inverse agonist activity of metoprolol.max. 4. In summary, the present study provides the first evidence of a change in the in vitro pharmacodynamic properties of metoprolol in SHR. The sympathetic overactivity present in SHR not only reduces the positive chronotropic effect of noradrenaline, but also diminishes the constant dissociation of metoprolol from atrial b1-adrenoceptors and its inverse agonist activity. A significant correlation between the VW/BW ratio and the inverse agonist potency of metoprolol was found, suggesting a possible link between cardiac hypertrophy and the reduction of the inverse agonist activity of metoprolol.in vitro pharmacodynamic properties of metoprolol in SHR. The sympathetic overactivity present in SHR not only reduces the positive chronotropic effect of noradrenaline, but also diminishes the constant dissociation of metoprolol from atrial b1-adrenoceptors and its inverse agonist activity. A significant correlation between the VW/BW ratio and the inverse agonist potency of metoprolol was found, suggesting a possible link between cardiac hypertrophy and the reduction of the inverse agonist activity of metoprolol.b1-adrenoceptors and its inverse agonist activity. A significant correlation between the VW/BW ratio and the inverse agonist potency of metoprolol was found, suggesting a possible link between cardiac hypertrophy and the reduction of the inverse agonist activity of metoprolol.P < 0.05). No difference was observed in the maximal response (Emax) of the concentration–time effect of metoprolol in WKY rats and SHR (−29.1 ± 7.1 vs −28.2 ± 8.5%, respectively; n = 6 for both). However, the concentration of metoprolol eliciting a half-maximal effect (expressed as the pEC50) was significantly smaller in SHR compared with WKY rats (4.82 ± 0.07 vs 5.29 ± 0.13, respectively; n = 6; P < 0.05). Although a significant correlation (r = – 0.876) between the ventricular weight/bodyweight (VW/ BW) ratio and the pEC50 of the chronotropic effect of metoprolol was found, no relationship (r = – 0.257) was found between the VW/BW ratio and Emax. 4. In summary, the present study provides the first evidence of a change in the in vitro pharmacodynamic properties of metoprolol in SHR. The sympathetic overactivity present in SHR not only reduces the positive chronotropic effect of noradrenaline, but also diminishes the constant dissociation of metoprolol from atrial b1-adrenoceptors and its inverse agonist activity. A significant correlation between the VW/BW ratio and the inverse agonist potency of metoprolol was found, suggesting a possible link between cardiac hypertrophy and the reduction of the inverse agonist activity of metoprolol.n = 6; P < 0.05). Although a significant correlation (r = – 0.876) between the ventricular weight/bodyweight (VW/ BW) ratio and the pEC50 of the chronotropic effect of metoprolol was found, no relationship (r = – 0.257) was found between the VW/BW ratio and Emax. 4. In summary, the present study provides the first evidence of a change in the in vitro pharmacodynamic properties of metoprolol in SHR. The sympathetic overactivity present in SHR not only reduces the positive chronotropic effect of noradrenaline, but also diminishes the constant dissociation of metoprolol from atrial b1-adrenoceptors and its inverse agonist activity. A significant correlation between the VW/BW ratio and the inverse agonist potency of metoprolol was found, suggesting a possible link between cardiac hypertrophy and the reduction of the inverse agonist activity of metoprolol.r = – 0.876) between the ventricular weight/bodyweight (VW/ BW) ratio and the pEC50 of the chronotropic effect of metoprolol was found, no relationship (r = – 0.257) was found between the VW/BW ratio and Emax. 4. In summary, the present study provides the first evidence of a change in the in vitro pharmacodynamic properties of metoprolol in SHR. The sympathetic overactivity present in SHR not only reduces the positive chronotropic effect of noradrenaline, but also diminishes the constant dissociation of metoprolol from atrial b1-adrenoceptors and its inverse agonist activity. A significant correlation between the VW/BW ratio and the inverse agonist potency of metoprolol was found, suggesting a possible link between cardiac hypertrophy and the reduction of the inverse agonist activity of metoprolol.50 of the chronotropic effect of metoprolol was found, no relationship (r = – 0.257) was found between the VW/BW ratio and Emax. 4. In summary, the present study provides the first evidence of a change in the in vitro pharmacodynamic properties of metoprolol in SHR. The sympathetic overactivity present in SHR not only reduces the positive chronotropic effect of noradrenaline, but also diminishes the constant dissociation of metoprolol from atrial b1-adrenoceptors and its inverse agonist activity. A significant correlation between the VW/BW ratio and the inverse agonist potency of metoprolol was found, suggesting a possible link between cardiac hypertrophy and the reduction of the inverse agonist activity of metoprolol.r = – 0.257) was found between the VW/BW ratio and Emax. 4. In summary, the present study provides the first evidence of a change in the in vitro pharmacodynamic properties of metoprolol in SHR. The sympathetic overactivity present in SHR not only reduces the positive chronotropic effect of noradrenaline, but also diminishes the constant dissociation of metoprolol from atrial b1-adrenoceptors and its inverse agonist activity. A significant correlation between the VW/BW ratio and the inverse agonist potency of metoprolol was foun

Unsteadiness in Flow over a Flat Plate at Angle-of-Attack at Low Reynolds Numbers

Flow over an impulsively started low-aspect-ratio flat plate at angle-of-attack is investigated for a Reynolds number of 300. Numerical simulations, validated by a companion experiment, are performed to study the influence of aspect ratio, angle of attack, and planform geometry on the interaction of the leading-edge and tip vortices and resulting lift and drag coefficients. Aspect ratio is found to significantly influence the wake pattern and the force experienced by the plate. For large aspect ratio plates, leading-edge vortices evolved into hairpin vortices that eventually detached from the plate, interacting with the tip vortices in a complex manner. Separation of the leading-edge vortex is delayed to some extent by having convective transport of the spanwise vorticity as observed in flow over elliptic, semicircular, and delta-shaped planforms. The time at which lift achieves its maximum is observed to be fairly constant over different aspect ratios, angles of attack, and planform geometries during the initial transient. Preliminary results are also presented for flow over plates with steady actuation near the leading edge

Cardiovascular drugs inducing QT prolongation: facts and evidence

Acquired QT syndrome is mainly caused by the administration of drugs that prolong ventricular repolarization. On the other hand, the risk of drug-induced torsades de pointes is increased by numerous predisposing factors, such as genetic predisposition, female sex, hypokalemia and cardiac dysfunction. This adverse reaction is induced by different chemical compounds used for the treatment of a variety of pathologies, including arrhythmias. As it is known, antiarrhythmic agents and other cardiovascular drugs can prolong the QT interval, causing this adverse reaction. Of the 20 most commonly reported drugs, 10 were cardiovascular agents and these appeared in 348 of the reports (46%). Class Ia antiarrhythmic agents have frequently been linked to inducing arrhythmia, including torsades de pointes. Sotalol and amiodarone, class III antiarrhythmics, are known to prolong the QT interval by blocking IKr. Due to the severity of events caused by the therapeutic use of these drugs, in this work of revision the cardiovascular drugs that present this property and the factors and evidence will be mentioned.Fil: Taira, Carlos Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Farmacología. Cátedra de Farmacología; ArgentinaFil: Opezzo, Javier A. W.. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Farmacología. Cátedra de Farmacología; ArgentinaFil: Mayer, Marcos Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Farmacología. Cátedra de Farmacología; ArgentinaFil: Höcht, Christian. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Farmacología. Cátedra de Farmacología; Argentin

Unsteady Aerodynamic Forces on Small-Scale Wings: Experiments, Simulations, and Models

The goal of this work is to develop low order dynamical systems models for the unsteady lift and drag forces on small wings in various modes of flight, and to better understand the physical characteristics of unsteady laminar separation. Velocity field and body force data for a flat plate at static angle of attack and in sinusoidal pitch and plunge maneuvers are generated by 2D direct numerical simulations using an immersed boundary method at Re = 100. The lift of a sinusoidally plunging plate is found to deviate from the quasi-steady approximation at a reduced frequency of k = 0.5 over a range of Strouhal numbers. Lagrangian coherent structures illustrate formation and convection of a leading-edge vortex in sinusoidal pitch and plunge. A phenomenological ODE model with three states is shown to reproduce the lift on a flat plate at a static angle of attack above the stall angle. DNS for a 3D pitch-up maneuver of a rectangular plate at Re = 300 shows the effect of aspect ratio on vortical wake structure and lift. Wind tunnel experiments of a wing in single pitch-up and sinusoidal pitch maneuvers are compared with a dynamic model incorporating time delays and relaxation times to produce hysteresis

Interseismic coupling and refined earthquake potential on the Hayward-Calaveras fault zone

Interseismic strain accumulation and fault creep is usually estimated from GPS and alignment arrays data, which provide precise but spatially sparse measurements. Here we use interferometric synthetic aperture radar to resolve the interseismic deformation associated with the Hayward and Calaveras Faults (HF and CF) in the East San Francisco Bay Area. The large 1992–2011 SAR data set permits evaluation of short- and long-wavelength deformation larger than 2 mm/yr without alignment of the velocity field to a GPS-based model. Our time series approach in which the interferogram selection is based on the spatial coherence enables deformation mapping in vegetated areas and leads to refined estimates of along-fault surface creep rates. Creep rates vary from 0 ± 2 mm/yr on the northern CF to 14 ± 2 mm/yr on the central CF south of the HF surface junction. We estimate the long-term slip rates by inverting the long-wavelength deformation and the distribution of shallow slip due to creep by inverting the remaining velocity field. This distribution of slip reveals the locations of locked and slowly creeping patches with potential for a M6.8 ± 0.3 on the HF near San Leandro, a M6.6 ± 0.2 on the northern CF near Dublin, a M6.5 ± 0.1 on the HF south of Fremont, and a M6.2 ± 0.2 on the central CF near Morgan Hill. With cascading multisegment ruptures the HF rupturing from Berkeley to the CF junction could produce a M6.9 ± 0.1, the northern CF a M6.6 ± 0.1, the central CF a M6.9 ± 0.2 from the junction to Gilroy, and a joint rupture of the HF and central CF could produce a M7.1 ± 0.1

Feedback Control of High-Lift State for A Low-Aspect-Ratio Wing

The objective of this study is to employ feedback control to maximize time-average lift on a low-aspect-ratio wing by directly modifying the three-dimensional dynamics of the wake vortices. Flow control around such wing at post-stall angles of attack is numerically investigated at a low Reynolds number of 300 with blowing along the trailing edge. Motivated by the existence of time-periodic high-lift states under open-loop control with periodic excitation, the extremum seeking algorithm is considered for designing feedback control to lock the flow onto such high-lift states. Preliminary results are presented where the close-loop control is able to seek the optimal actuation frequency and yield high lift